We see evidence dating back to 2017 that Johnson & Johnson has been regularly publishing about their investments and initiatives related to artificial intelligence. At present, Johnson & Johnson does not seem to boast any mature, deployed applications with the firm itself, but its AI-related investment initiatives indicate their aspirations. According to an analysis by FiercePharma, Johnson & Johnson (J&J) is the largest pharmaceutical firm by revenue, bringing in $82.1 billion in 2019. However, its pharma group has seen the lions' share of J&J's success, outperforming its other units with notable sales expansion in oncology and immunology. J&J claims to be investing in data science competency throughout the firm.